“…Among the risks of degenerative joint disease that increases with age, the increased risk of AVN from immunosuppressive medications and/or graft versus host disease, and the growing number of patients undergoing stem-cell transplantation, it seems likely that the number of such patients undergoing elective THA will increase. However, with a high incidence of medical comorbidities, immunosuppressive regimens, and often diminished numbers of circulating hematopoietic cell lines, these patients undergoing THA are at a potentially greater risk for perioperative complications [2,11,12]. We sought to determine the mortality, complications, and implant survivorship in this difficult-to-treat cohort undergoing THA at our institution.…”